Abstract Number: 1836 • ACR Convergence 2023
Embracing a Biopsychosocial Approach to Fibromyalgia-like Symptoms in People with SLE: Insights from the Type 2 SLE Consortium
Background/Purpose: Patients with SLE experience distressing fibromyalgia-like symptoms of fatigue, widespread pain, mood disturbance, and brain fog that negatively impact quality of life and are…Abstract Number: 2212 • ACR Convergence 2023
Interpretation of Disease-specific Questionnaires on Disease Activity, Functional Capacity and Quality of Life in Daily Practice in Axial Spondyloarthritis
Background/Purpose: In axial spondyloarthritis (axSpA), assessment of disease activity and physical function in clinical studies relies on patient-reported outcomes (PRO) such as patient's global, BASDAI,…Abstract Number: PP15 • ACR Convergence 2023
Toward a Frontier Beyond the Barriers of Position and Prejudice
Background/Purpose: In Japan, firm boundaries exist between people from different walks of life surrounding diseases. 【Patients】Some patients are unable to assert themselves before doctors who…Abstract Number: 0146 • ACR Convergence 2023
Sexual Health and Self-Perception in Rheumatologic Patients: Has Your Rheumatologist Ever Talked to You About Sexual Health?
Background/Purpose: There's a high prevalence of sexual dysfunction (SD) in patients with rheumatic diseases (RD). Studies show that it goes from a 36% to a…Abstract Number: 0525 • ACR Convergence 2023
Bimekizumab Achieved Sustained Improvements in Efficacy Outcomes in Patients with Axial Spondyloarthritis, Regardless of Prior TNF Inhibitor Treatment: Week 52 Pooled Results from Two Phase 3 Studies
Background/Purpose: In patients (pts) with axial spondyloarthritis (axSpA), tumor necrosis factor inhibitors (TNFi) are the usual first line biologic treatment, yet many pts may experience…Abstract Number: 1170 • ACR Convergence 2023
Damage Accrual in Idiopathic Inflammatory Myopathies: Data from a Monocentric Cohort and Impact on Patients’ Quality of Life
Background/Purpose: Although the prognosis of Idiopathic Inflammatory Myopathies (IIMs) has noticeably improved over time, their chronicity may still expose a considerable number of patients to…Abstract Number: 1838 • ACR Convergence 2023
The Burden of Dysautonomia in Patients Suffering from Pathologies Associated with Generalized Joint Hypermobility
Background/Purpose: Hypermobility spectrum disorders (HSD) and hypermobile Ehlers Danlos syndrome (hEDS) are among the conditions associated with generalized joint hypermobility (GJH). Alongside myofascial and skeletal…Abstract Number: 2249 • ACR Convergence 2023
Bimekizumab-Treated Patients with Active PsA Showed Sustained Improvement in Disease Symptoms Assessed by the PsA Impact of Disease (PsAID)-12 Questionnaire: 1-Year Results Reported from Two Phase 3 Studies
Background/Purpose: The PsA Impact of Disease‑12 (PsAID‑12) questionnaire is a patient (pt)-reported outcome measure assessing the impact of PsA on 12 physical, social, and psychological…Abstract Number: PP17 • ACR Convergence 2023
Utilizing Support Networks to Improve Patient Outcomes
Background/Purpose: In 2006, I realized I was gay and identified as LGBTQIA but did not come out. In 2008, I began experiencing chronic widespread pain,…Abstract Number: 0148 • ACR Convergence 2023
Recreational Activities in Adults with Rheumatoid Arthritis: Relevance, Difficulty, and Associations with Clinical Outcomes
Background/Purpose: Rheumatoid arthritis (RA) can limit one's ability to participate in recreational activities. Participation in recreational activities enhances quality of life, yet limited literature addresses…Abstract Number: 0526 • ACR Convergence 2023
Bimekizumab Improved Physical Function and Health-Related Quality of Life in Patients with Axial Spondyloarthritis: 52-Week Results from Two Phase 3 Studies
Background/Purpose: Axial spondyloarthritis (axSpA) severely impairs physical function and health-related quality of life (HRQoL).1 Bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits IL-17F in…Abstract Number: 1201 • ACR Convergence 2023
Frailty and Its Impact on Patient Reported Outcomes in Polymyalgia Rheumatica
Background/Purpose: Frailty is an increasingly important construct in the field of rheumatology, aiding the identification of individuals with increased vulnerability to accelerated clinical decline and…Abstract Number: 1846 • ACR Convergence 2023
A Longitudinal Study: The Benefits of Non-Pharmacological Approaches to Improve Self-Reported Pain, Stiffness, and Fatigue in Individuals with Musculoskeletal Disorders
Background/Purpose: Musculoskeletal disorders are a leading cause of disability worldwide, with low back pain being one of the primary causes. The World Health Organization (WHO)…Abstract Number: 2250 • ACR Convergence 2023
Bimekizumab Impact on Health-Related Quality of Life and Physical Function in Patients with Active Psoriatic Arthritis Who Were Biologic DMARD‑Naïve or Had Inadequate Response or Intolerance to TNF-α Inhibitors: 1-Year Results from Two Phase 3, Randomized Studies
Background/Purpose: PsA has a substantial negative impact on patient (pt) health-related quality of life (HRQoL);1 symptom control, preventing structural damage, and normalizing physical and social…Abstract Number: 0171 • ACR Convergence 2023
A Conceptual Framework to Characterize the Indirect Burden of Systemic Lupus Erythematosus (SLE): Findings from Qualitative Patient Interviews
Background/Purpose: SLE is a chronic autoimmune disorder that affects multiple organs and leads to a variety of symptoms, including joint pain, fatigue, and skin rashes,…
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- …
- 25
- Next Page »